Home › Colorectal Cancer › NCT07310446
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance (PROVE)
Who can join
Ages 45 to 84 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Arm A: Diagnosed with CRC * Arm B: Undergoing screening with colonoscopy for CRC Exclusion Criteria: * Arm A: Undergoing treatment for CRC, * Arm B: Past history of CRC
About the study
This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological confirmation of CRC from the diagnostic colonoscopy and clinical staging (cTMN) is available and are pr e- treatment, and patients who are at average risk of colorectal cancer and who are scheduled for routine colonoscopy examinations.
Sponsor: Universal Diagnostics · Participants: 6,500 · Started: Jul 31, 2023
Contact the study team
- Antonio Jesus Merino Calvo · Phone: 674945571
Official record on ClinicalTrials.gov — NCT07310446
Locations in the U.S.
| Illinois | Gastroenterology and Internal Medicine Specialists, Lake Barrington |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.